En bref
Frans van Houten, CEO de Royal Philips : « Sur l’ensemble de nos unités opérationnelles, nous avons renforcé nos actions en matière de productivité, de tarification et de résilience de la chaîne d’approvisionnement afin d’atténuer les effets de contretemps actuels et les risques associés. La conséquence positive de ces actions, conjuguée à la solidité de notre carnet de commandes et à l’amélioration de l’approvisionnement en composants, me rendent confiant quant à notre capacité à retrouver notre croissance dès le troisième trimestre avec, à la clé, une croissance des ventes comparable de 6 à 9 % et une rentabilité accrue pour la seconde moitié de l’exercice. Pour la totalité de l’exercice 2022, nous nous attendons à atteindre une croissance comparable des ventes de 1 à 3 % et une marge d'EBITA ajustée d'environ 10 %.
Nos produits enregistrent toujours un bon niveau de demande, comme le montre la croissance continue de notre carnet de commandes déjà bien solide, ce qui confirme la pertinence de notre stratégie et de notre portefeuille d’innovation à destination de nos clients. Au cours du second trimestre, la prise de commande comparable a augmenté d’1 %, compte tenu de l’impact négatif de 5 points de pourcentage lié à la situation en Chine. Nous avons conclu des partenariats avec 19 groupes hospitaliers supplémentaires afin de les aider à transformer leur prestation de soins et de stimuler la productivité de leur personnel. Dans nos entités dédiées à la santé individuelle, nous avons obtenu une croissance des ventes comparable à deux chiffres pour le second trimestre consécutif en Amérique du Nord.
Au cours du second trimestre, nos performances ont pâti des défis industriels à l’échelle mondiale, y compris des pénuries d’approvisionnement, les mesures de confinement liées à la COVID en Chine, les pressions inflationnistes et le conflit entre la Russie et l’Ukraine, ce qui a entraîné une baisse de 7 %, avec une marge d'EBITA ajustée de 5,2%. Les confinements liés à la COVID ont affecté notre activité en Chine, où les ventes comparables et la prise de commandes ont chuté de près de 30 % au cours du trimestre. Dans plusieurs de nos usines, ainsi que celles de nos fournisseurs en Chine, la production a été à l’arrêt pendant deux mois, ce qui a exacerbé la chaîne d’approvisionnement et les tensions sur les coûts au niveau mondial. Les confinements en Chine ont eu un impact direct sur la marge d’EBITA ajustée du Groupe de 120 points de base en raison de la baisse des ventes et de 110 points de base supplémentaires en raison de la sous-utilisation des usines. L’inflation mondiale ainsi que la hausse des coûts ont eu un impact supplémentaire d’environ 290 points de base sur la rentabilité du Groupe au cours du trimestre.
Philips Respironics continue d’afficher une solide progression avec le programme de réparation et de remplacement pour les appareils de CPAP, BiPAP et appareils de ventilation mécanique concernés par la notification de sécurité de juin 2021 et a publié des résultats encourageants à la suite du programme exhaustif de recherches et de tests destiné à évaluer les risques potentiels pour la santé. Nous savons à quel point les appareils concernés sont importants pour les patients et nous travaillons activement afin de résoudre ce problème au plus vite.
Si l’on se projette à l’horizon 2023 et au-delà, malgré les risques persistants et un environnement macroéconomique complexe, nous prévoyons que les mesures relatives à la chaîne d’approvisionnement soient pleinement d’application, avec une franche amélioration de la conversion de nos commandes en chiffre d’affaires. Nos mesures relatives aux tarifs et à la hausse de productivité auront pour effet d’augmenter les marges. À partir de ces actions, les fondamentaux de nos unités opérationnelles, et les perspectives pour 2022, nous pouvons maintenant envisager une croissance des ventes comparable de l’ordre de 4 à 6 % et une marge d'EBITA ajustée de 14 à 15 % d’ici 2025, avec une situation qui devrait continuer à s’améliorer par la suite. »
Business segment performance
The Diagnosis & Treatment businesses’ comparable sales decreased 4% on the back of 16% comparable sales growth in Q2 2021. High-single-digit growth in Enterprise Diagnostic Informatics and mid-single-digit growth in Image-Guided Therapy was more than offset by a decline in Ultrasound and Diagnostic Imaging, due to specific electronic component shortages. Comparable order intake increased 3% on the back of 29% comparable order intake growth in Q2 2021, with growth across all businesses, reflecting ongoing solid demand for Philips’ portfolio. The Adjusted EBITA margin was 6.2%, mainly due to the decline in sales, cost inflation and an unfavorable mix impact, partly offset by productivity measures.
The Connected Care businesses’ comparable sales decreased 13%, mainly due to the consequences of the Respironics field action and the impact of supply chain headwinds. Comparable order intake showed a 2% decrease, while demand for Hospital Patient Monitoring and Connected Care Informatics remains robust. The Adjusted EBITA margin amounted to 1.1%, mainly due to the decline in sales and cost inflation, partly offset by productivity measures.
The Personal Health businesses’ comparable sales decreased by 5% on the back of 33% comparable sales growth in Q2 2021. Double- digit growth in North America was more than offset by double-digit declines in China and Russia. The Adjusted EBITA margin amounted to 12.4%, mainly due to the decline in sales and cost inflation.
Philips’ ongoing focus on innovation and customer partnerships resulted in the following key developments in the quarter:
Philips Respironics field action related to specific CPAP, BiPAP and mechanical ventilators
Philips Respironics continued to make solid progress with the repair and replacement program for the CPAP, BiPAP and mechanical ventilator devices affected by the June 2021 field safety notice, as well as the comprehensive test and research program to assess the possible health risks. To date, 3 million replacement devices and repair kits have been produced. Philips Respironics aims to further increase capacity and complete around 90% of the production and shipments to customers in 2022. The test results to date for the first-generation DreamStation devices, which represent the majority of the registered affected devices, are very encouraging. They show a very low prevalence of visible foam degradation, and new and used first-generation DreamStation devices passed volatile organic compound and respirable particulate emission testing.
Following the FDA’s inspection of certain of Philips Respironics’ facilities in the US in 2021 and the subsequent inspectional observations, the US Department of Justice, acting on behalf of the FDA, recently began discussions with Philips regarding the terms of a proposed consent decree to resolve the identified issues.
Capital allocation
In the second quarter, Philips issued EUR 750 million fixed-rate notes due 2027, EUR 650 million Green Innovation Notes due 2029 and EUR 600 million Sustainability Innovation Notes due 2033 under its Euro Medium Term Note program, and entered into a series of transactions to extend and optimize the company’s debt maturity profile. See here for more information on Philips' current debt structure.
Following the issuance of 14,174,568 new shares related to the share dividend, and the cancellation of 8,758,455 shares that were acquired as part of the EUR 1.5 billion share repurchase program for capital reduction purposes, Philips’ current issued share capital amounts to 889,315,082 common shares. As communicated earlier, Philips intends to have 19,571,218 shares delivered through the early settlement of forward contracts (entered into as part of the same share repurchase program) and to cancel those as well, which would result in 869,743,864 issued common shares at year-end 2022 (2021: 883,898,969).
Report
Presentation
Conference call and video webcast Frans van Houten, CEO, and Abhijit Bhattacharya, CFO, will host a conference call for investors and analysts at 10:00 am CET today to discuss the results, as well as the company’s mid-term performance roadmap. They will be joined by Roy Jakobs, Chief Business Leader Connected Care, and Francis Kim, Chief Quality & Regulatory Officer, who will provide further details on the Respironics field action and on Philips’ progress and continued efforts around quality, respectively. A live video webcast of the conference call will be available on the Philips Investor Relations website and can be accessed here. Click here for Mr. Bhattacharya's CV and images
More information about Frans van Houten and Abhijit Bhattacharya
Click here for Mr. van Houten's CV and images
Visit our interactive results hub for more on our financial and sustainability performance over the past quarter.
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Forward-looking statements
This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future Adjusted EBITA*), future restructuring and acquisition- related charges and other costs, future developments in Philips’ organic business and the completion of acquisitions and divestments. Forward-looking statements can be identified generally as those containing words such as “anticipates”, “assumes”, “believes”, “estimates”, “expects”, “should”, “will”, “will likely result”, “forecast”, “outlook”, “projects”, “may” or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
These factors include but are not limited to: Philips’ ability to gain leadership in health informatics in response to developments in the health technology industry; Philips’ ability to transform its business model to health technology solutions and services; macroeconomic and geopolitical changes; integration of acquisitions and their delivery on business plans and value creation expectations; securing and maintaining Philips’ intellectual property rights, and unauthorized use of third-party intellectual property rights; Philips' ability to meet expectations with respect to ESG-related matters; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations; breaches of cybersecurity; Philips' ability to execute and deliver on programs on business transformation and IT system changes and continuity; the effectiveness of our supply chain; attracting and retaining personnel; COVID and other pandemics; challenges to drive operational excellence and speed in bringing innovations to market; compliance with regulations and standards including quality, product safety and (cyber) security; compliance with business conduct rules and regulations; treasury and financing risks; tax risks; reliability of internal controls, financial reporting and management process. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Risk management chapter included in the Annual Report 2021. Reference is also made to Risk management in the Philips semi-annual report 2022.
Third-party market share data
Statements regarding market share, contained in this document, including those regarding Philips’ competitive position, are based on outside sources such as specialized research institutes, industry and dealer panels in combination with management estimates. Where information is not yet available to Philips, market share statements may also be based on estimates and projections prepared by management and/or based on outside sources of information. Management's estimates of rankings are based on order intake or sales, depending on the business.
Market Abuse Regulation
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. This press release was distributed at 07:00 am CET on July 25, 2022.
Use of non-IFRS information
In presenting and discussing the Philips Group’s financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2021.
Use of fair value information
In presenting the Philips Group’s financial position, fair values are used for the measurement of various items in accordance with the applicable accounting standards. These fair values are based on market prices, where available, and are obtained from sources that are deemed to be reliable. Readers are cautioned that these values are subject to changes over time and are only valid at the balance sheet date. When quoted prices or observable market data are not readily available, fair values are estimated using appropriate valuation models and unobservable inputs. Such fair value estimates require management to make significant assumptions with respect to future developments, which are inherently uncertain and may therefore deviate from actual developments. Critical assumptions used are disclosed in the Annual Report 2021 In certain cases independent valuations are obtained to support management’s determination of fair values.
Presentation
All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to the totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2021 except for the adoption of new standards and amendments to standards which are also expected to be reflected in the company's consolidated financial statements for the year ending December 31, 2022.
Prior-period amounts have been reclassified to conform to the current-period presentation; this includes immaterial organizational changes.
*) Non-IFRS financial measure. Refer to the Reconciliation of non-IFRS information
Philips Global Press Office Tel: +31 6 1521 3446
You are about to visit a Philips global content page
Continue Philips Investor Relations Tel: +31 20 59 77055
You are about to visit a Philips global content page
Continue New long-term strategic partnerships
Philips signed 19 new long-term strategic partnerships with hospitals in Europe, Asia, and North America, including a 10-year patient monitoring agreement with a large hospital in Germany.
FDA clearance for diagnostic imaging innovations
Philips received FDA clearance to market its new 7700 3.0T MR system, featuring an enhanced gradient system for Philips’ highest image quality to support a precision diagnosis.
Image guidance innovation for interventional cardiology
Building on Philips’ leadership in interventional cardiology solutions, the company launched the latest version of its EchoNavigator image-guidance tool.
Strong momentum for oral healthcare innovations in North America
Building on the successful strengthening of the company’s innovative power toothbrushes portfolio, Philips Oral Healthcare recorded continued strong double-digit comparable sales growth and market share gains in North America in the quarter.